SP-600125 | CAS#129-56-6 | JNK inhibitor

MedKoo Cat#: 406236 | Name: SP-600125

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SP-600125 is a specific JNK inhibitor. SP-600125 kills p53-deficient cells more efficiently than their p53-proficient counterparts, in vitro. Similar observations were obtained in vivo, in mice carrying p53-deficient and -proficient human xenografts.

Chemical Structure

SP-600125

CAS#129-56-6

Theoretical Analysis

MedKoo Cat#: 406236

Name: SP-600125

CAS#: 129-56-6

Chemical Formula: C14H8N2O

Exact Mass: 220.0637

Molecular Weight: 220.23

Elemental Analysis: C, 76.35; H, 3.66; N, 12.72; O, 7.26

Price and Availability

Size	Price	Availability
100mg	USD 250.00	2 Weeks
200mg	USD 350.00	2 Weeks
500mg	USD 500.00	2 Weeks
1g	USD 800.00	2 Weeks
2g	USD 1,150.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

SP600125; SP 600125; SP-600125.

IUPAC/Chemical Name

dibenzo[cd,g]indazol-6(2H)-one

InChi Key

ACPOUJIDANTYHO-UHFFFAOYSA-N

InChi Code

InChI=1S/C14H8N2O/c17-14-9-5-2-1-4-8(9)13-12-10(14)6-3-7-11(12)15-16-13/h1-7H,(H,15,16)

SMILES Code

O=C1C2=C3C(NN=C3C4=CC=CC=C14)=CC=C2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

SP-600125 is an orally active, reversible, and ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively.

In vitro activity:

SP-600125 prevents the entry of cells into mitosis and leads to endoreplication of DNA from G2 phase. In the absence of mitosis, cells proceed from G2 phase to replicate their DNA. The inhibitory effect of SP-600125 on mitotic entry predominantly occurs upstream of Aurora A kinase and Polo-like kinase 1, resulting in a failure to remove the inhibitory phosphorylation of Cdk1. Reference: Oncogene. 2010 Mar 18;29(11):1702-16. https://pubmed.ncbi.nlm.nih.gov/20062077/

In vivo activity:

SP-600125 protected against LPS-induced acute lung injury (ALI), possibly by upregulating the expression of claudin-4. After in vivo treatment of SP-600125, pulmonary edema, the expression of inflammatory cytokines and pathological alterations were significantly attenuated in LPS-induced ALI. Reference: Exp Ther Med. 2014 Jul;8(1):153-158. https://pubmed.ncbi.nlm.nih.gov/24944614/

	Solvent	mg/mL	mM
Solubility
	DMSO	12.5	56.76

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 220.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Kim JA, Lee J, Margolis RL, Fotedar R. SP600125 suppresses Cdk1 and induces endoreplication directly from G2 phase, independent of JNK inhibition. Oncogene. 2010 Mar 18;29(11):1702-16. doi: 10.1038/onc.2009.464. Epub 2010 Jan 11. PMID: 20062077; PMCID: PMC3145494. 2. Shen J, Hong Y, Zhao Q, Zhang JL. Preclinical evaluation of perifosine as a potential promising anti-rhabdomyosarcoma agent. Tumour Biol. 2016 Jan;37(1):1025-33. doi: 10.1007/s13277-015-3740-4. Epub 2015 Aug 13. PMID: 26269112. 3. Zheng Y, Zhang M, Zhao Y, Chen J, Li B, Cai W. JNK inhibitor SP600125 protects against lipopolysaccharide-induced acute lung injury via upregulation of claudin-4. Exp Ther Med. 2014 Jul;8(1):153-158. doi: 10.3892/etm.2014.1684. Epub 2014 Apr 14. PMID: 24944614; PMCID: PMC4061205. 4. Pérez-Girón JV, Palacios R, Martín A, Hernanz R, Aguado A, Martínez-Revelles S, Barrús MT, Salaices M, Alonso MJ. Pioglitazone reduces angiotensin II-induced COX-2 expression through inhibition of ROS production and ET-1 transcription in vascular cells from spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2014 Jun 1;306(11):H1582-93. doi: 10.1152/ajpheart.00924.2013. Epub 2014 Apr 11. PMID: 24727493.

In vitro protocol:

In vivo protocol:

1. Zheng Y, Zhang M, Zhao Y, Chen J, Li B, Cai W. JNK inhibitor SP600125 protects against lipopolysaccharide-induced acute lung injury via upregulation of claudin-4. Exp Ther Med. 2014 Jul;8(1):153-158. doi: 10.3892/etm.2014.1684. Epub 2014 Apr 14. PMID: 24944614; PMCID: PMC4061205. 2. Pérez-Girón JV, Palacios R, Martín A, Hernanz R, Aguado A, Martínez-Revelles S, Barrús MT, Salaices M, Alonso MJ. Pioglitazone reduces angiotensin II-induced COX-2 expression through inhibition of ROS production and ET-1 transcription in vascular cells from spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2014 Jun 1;306(11):H1582-93. doi: 10.1152/ajpheart.00924.2013. Epub 2014 Apr 11. PMID: 24727493.

1: Konno T, Ninomiya T, Kohno T, Kikuchi S, Sawada N, Kojima T. c-Jun N-terminal kinase inhibitor SP600125 enhances barrier function and elongation of human pancreatic cancer cell line HPAC in a Ca-switch model. Histochem Cell Biol. 2014 Dec 16. [Epub ahead of print] PubMed PMID: 25511417. 2: Li CL, Yang JG, Lin D, Zhao YS, Liu S, Xing SN, Zhao S, Chen CQ, Jiang ZM, Pu FF, Cao JP, Ma DC. Phosphorylation of ribosomal protein S6 kinase 1 at Thr421/Ser424 and dephosphorylation at Thr389 regulates SP600125-induced polyploidization of megakaryocytic cell lines. PLoS One. 2014 Dec 8;9(12):e114389. doi: 10.1371/journal.pone.0114389. eCollection 2014. PubMed PMID: 25486532; PubMed Central PMCID: PMC4259319. 3: Kong Q, Hua H, Cui A, Shao T, Song P, Jiang Y. SP600125 induces Src and type I IGF receptor phosphorylation independent of JNK. Int J Mol Sci. 2014 Sep 15;15(9):16246-56. doi: 10.3390/ijms150916246. PubMed PMID: 25226534; PubMed Central PMCID: PMC4200863. 4: Cao S, Wang T, Yan B, Lu Y, Guo W, Zhang S. Protective effects of SP600125 in brain death-induced liver injury. Clin Res Hepatol Gastroenterol. 2014 Oct;38(5):577-82. doi: 10.1016/j.clinre.2014.05.004. Epub 2014 Jun 23. PubMed PMID: 24969683. 5: Zheng Y, Zhang M, Zhao Y, Chen J, Li B, Cai W. JNK inhibitor SP600125 protects against lipopolysaccharide-induced acute lung injury via upregulation of claudin-4. Exp Ther Med. 2014 Jul;8(1):153-158. Epub 2014 Apr 14. PubMed PMID: 24944614; PubMed Central PMCID: PMC4061205. 6: Jung EJ, Park HC, Chung KH, Kim CW. Proteomic analysis of SP600125-controlled TrkA-dependent targets in SK-N-MC neuroblastoma cells: inhibition of TrkA activity by SP600125. Proteomics. 2014 Feb;14(2-3):202-15. doi: 10.1002/pmic.201300023. PubMed PMID: 24375967. 7: Kim JH, Chae M, Choi AR, Sik Kim H, Yoon S. SP600125 overcomes antimitotic drug-resistance in cancer cells by increasing apoptosis with independence of P-gp inhibition. Eur J Pharmacol. 2014 Jan 15;723:141-7. doi: 10.1016/j.ejphar.2013.11.026. Epub 2013 Dec 12. PubMed PMID: 24333214. 8: Urrutia A, Granado N, Gutierrez-Lopez MD, Moratalla R, O'Shea E, Colado MI. The JNK inhibitor, SP600125, potentiates the glial response and cell death induced by methamphetamine in the mouse striatum. Int J Neuropsychopharmacol. 2014 Feb;17(2):235-46. doi: 10.1017/S1461145713000850. Epub 2013 Oct 8. PubMed PMID: 24103647. 9: Lin Y, Zhang B, Liang H, Lu Y, Ai X, Zhang B, Chen X. JNK inhibitor SP600125 enhances TGF-β-induced apoptosis of RBE human cholangiocarcinoma cells in a Smad-dependent manner. Mol Med Rep. 2013 Dec;8(6):1623-9. doi: 10.3892/mmr.2013.1711. Epub 2013 Oct 2. PubMed PMID: 24100678. 10: Kusakabe K, Ide N, Daigo Y, Tachibana Y, Itoh T, Yamamoto T, Hashizume H, Hato Y, Higashino K, Okano Y, Sato Y, Inoue M, Iguchi M, Kanazawa T, Ishioka Y, Dohi K, Kido Y, Sakamoto S, Yasuo K, Maeda M, Higaki M, Ueda K, Yoshizawa H, Baba Y, Shiota T, Murai H, Nakamura Y. Indazole-based potent and cell-active Mps1 kinase inhibitors: rational design from pan-kinase inhibitor anthrapyrazolone (SP600125). J Med Chem. 2013 Jun 13;56(11):4343-56. doi: 10.1021/jm4000215. Epub 2013 May 24. PubMed PMID: 23634759. 11: Anand SS, Maruthi M, Babu PP. The specific, reversible JNK inhibitor SP600125 improves survivability and attenuates neuronal cell death in experimental cerebral malaria (ECM). Parasitol Res. 2013 May;112(5):1959-66. doi: 10.1007/s00436-013-3352-0. Epub 2013 Feb 28. PubMed PMID: 23455938. 12: Li JY, Huang JY, Xing B, Ren KW, Li M, Wei D, Gu PY, Chen G, Gu B, Zhang GF, Hu WX. SP600125, a JNK inhibitor, suppresses growth of JNK-inactive glioblastoma cells through cell-cycle G2/M phase arrest. Pharmazie. 2012 Nov;67(11):942-6. PubMed PMID: 23210245. 13: Urrutia A, Rubio-Araiz A, Gutierrez-Lopez MD, ElAli A, Hermann DM, O'Shea E, Colado MI. A study on the effect of JNK inhibitor, SP600125, on the disruption of blood-brain barrier induced by methamphetamine. Neurobiol Dis. 2013 Feb;50:49-58. doi: 10.1016/j.nbd.2012.10.006. Epub 2012 Oct 12. PubMed PMID: 23069681. 14: Qiu XX, Dai YY, Song ZJ, Fang ZX, Wang WT. [Protective effects and mechanism of SP600125 on lung ischemia/reperfusion injury in rats]. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2012 May;28(3):255-8. Chinese. PubMed PMID: 22860429. 15: JemaÃ M, Vitale I, Kepp O, Berardinelli F, Galluzzi L, Senovilla L, MariÃ±o G, Malik SA, Rello-Varona S, Lissa D, Antoccia A, Tailler M, Schlemmer F, Harper F, Pierron G, Castedo M, Kroemer G. Selective killing of p53-deficient cancer cells by SP600125. EMBO Mol Med. 2012 Jun;4(6):500-14. doi: 10.1002/emmm.201200228. Epub 2012 Mar 21. PubMed PMID: 22438244; PubMed Central PMCID: PMC3443949. 16: Strittmatter F, Walther S, Gratzke C, GÃ¶ttinger J, Beckmann C, Roosen A, Schlenker B, Hedlund P, Andersson KE, Stief CG, Hennenberg M. Inhibition of adrenergic human prostate smooth muscle contraction by the inhibitors of c-Jun N-terminal kinase, SP600125 and BI-78D3. Br J Pharmacol. 2012 Jul;166(6):1926-35. doi: 10.1111/j.1476-5381.2012.01919.x. PubMed PMID: 22364229; PubMed Central PMCID: PMC3402815. 17: Rahman M, Zhang Z, Mody AA, Su DM, Das HK. Intraperitoneal injection of JNK-specific inhibitor SP600125 inhibits the expression of presenilin-1 and Notch signaling in mouse brain without induction of apoptosis. Brain Res. 2012 Apr 11;1448:117-28. doi: 10.1016/j.brainres.2012.01.066. Epub 2012 Feb 3. PubMed PMID: 22353755; PubMed Central PMCID: PMC3310381. 18: Marozin S, Altomonte J, Apfel S, Dinh PX, De Toni EN, Rizzani A, NÃ¼ssler A, Kato N, Schmid RM, Pattnaik AK, Ebert O. Posttranslational modification of vesicular stomatitis virus glycoprotein, but not JNK inhibition, is the antiviral mechanism of SP600125. J Virol. 2012 May;86(9):4844-55. doi: 10.1128/JVI.06649-11. Epub 2012 Feb 15. PubMed PMID: 22345438; PubMed Central PMCID: PMC3347359. 19: Pereira AC, Soares-Martins JA, Leite FG, Da Cruz AF, Torres AA, Souto-PadrÃ³n T, Kroon EG, Ferreira PC, Bonjardim CA. SP600125 inhibits Orthopoxviruses replication in a JNK1/2 -independent manner: Implication as a potential antipoxviral. Antiviral Res. 2012 Jan;93(1):69-77. doi: 10.1016/j.antiviral.2011.10.020. Epub 2011 Nov 2. PubMed PMID: 22068148. 20: Liu H, Sun H, Liu C. Interference of the apoptotic signaling pathway in RGC stress response by SP600125 in moderate ocular hypertensive rats. Chin J Physiol. 2011 Apr 30;54(2):124-32. Erratum in: Chin J Physiol. 2011 Jun 30;54(3):203. PubMed PMID: 21789894.